Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2012-04

AUTHORS

S Bracarda, T E Hutson, C Porta, R A Figlin, E Calvo, V Grünwald, A Ravaud, R Motzer, D Kim, O Anak, A Panneerselvam, B Escudier

ABSTRACT

BACKGROUND: A relevant percentage of patients with metastatic renal cell carcinoma develop intolerance to vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFr-TKIs) and require careful selection of subsequent treatment. This retrospective analysis evaluated the safety and efficacy of everolimus in patients enrolled in the phase-III RECORD-1 trial who discontinued previous VEGFr-TKI therapy because of toxicity. METHODS: Patients with an adverse event (AE) as their primary reason for discontinuation of previous VEGFr-TKI therapy were included. Median progression-free survival (PFS) for VEGFr-TKI-intolerant patients in each arm was estimated using the Kaplan-Meier method, and effect on PFS (hazard ratio (HR)) was calculated using the Cox proportional hazard model. RESULTS: In VEGFr-TKI-intolerant patients (n=58, 14%), median PFS was 5.4 months with everolimus and 1.9 months with placebo (HR: 0.32; P=0.004). In sunitinib-intolerant patients (n=26), median PFS was 5.1 months with everolimus and 2.8 months with placebo (HR: 0.28; P=0.033). Grade 3/4 AEs reported with everolimus in VEGFr-TKI-intolerant patients included infections (16%), fatigue (7%) and stomatitis (4%). The toxicity profile of everolimus was similar in the VEGFr-TKI-intolerant and overall study populations. CONCLUSION: Everolimus is well tolerated and efficacious with no increased toxicity in patients intolerant to VEGFr-TKI therapy. More... »

PAGES

1475

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/bjc.2012.89

DOI

http://dx.doi.org/10.1038/bjc.2012.89

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1041870192

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/22441644


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Renal Cell", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Double-Blind Method", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Everolimus", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunosuppressive Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "International Agencies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kidney Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lymphatic Metastasis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Protein Kinase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptors, Vascular Endothelial Growth Factor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Salvage Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sirolimus", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Rate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Ospedale San Donato", 
          "id": "https://www.grid.ac/institutes/grid.416351.4", 
          "name": [
            "Ospedale San Donato USL8, Istituto Toscano Tumori (ITT), Via Pietro Nenni, 20 52100 Arezzo, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bracarda", 
        "givenName": "S", 
        "id": "sg:person.0672107754.22", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0672107754.22"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "US Oncology/Baylor\u2013Sammons Cancer Center, 3535 Worth Street, Dallas, TX 75246, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hutson", 
        "givenName": "T E", 
        "id": "sg:person.0626761272.86", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0626761272.86"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Policlinico San Matteo Fondazione", 
          "id": "https://www.grid.ac/institutes/grid.419425.f", 
          "name": [
            "IRCCS San Matteo University Hospital Foundation, Piazzale C. Golgi 19, Pavia I-27100, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Porta", 
        "givenName": "C", 
        "id": "sg:person.01100733105.43", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01100733105.43"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cedars-Sinai Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.50956.3f", 
          "name": [
            "Samuel Oschin Comprehensive Cancer Institute, Cedars\u2013Sinai Medical Center, 8700 Beverly Boulevard, AC 1085 North Tower, Los Angeles, CA 90048, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Figlin", 
        "givenName": "R A", 
        "id": "sg:person.0664152550.77", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0664152550.77"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "HM Hospitales", 
          "id": "https://www.grid.ac/institutes/grid.428486.4", 
          "name": [
            "START Madrid, Centro Integral Oncol\u00f3gico Clara Campal, Hospital Madrid Norte Sanchinarro, 28050 Madrid, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Calvo", 
        "givenName": "E", 
        "id": "sg:person.01213300245.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01213300245.49"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hannover Medical School", 
          "id": "https://www.grid.ac/institutes/grid.10423.34", 
          "name": [
            "Medical School Hannover, Carl Neuberg Street 1, D-30627 Hannover, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gr\u00fcnwald", 
        "givenName": "V", 
        "id": "sg:person.01315730111.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01315730111.15"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "H\u00f4pital Saint-Andr\u00e9", 
          "id": "https://www.grid.ac/institutes/grid.414339.8", 
          "name": [
            "H\u00f4pital Saint Andr\u00e9 CHU, 1 rue Jean Burguet, 33075 Bordeaux, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ravaud", 
        "givenName": "A", 
        "id": "sg:person.01077045011.19", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01077045011.19"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Memorial Sloan Kettering Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.51462.34", 
          "name": [
            "Memorial Sloan\u2013Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Motzer", 
        "givenName": "R", 
        "id": "sg:person.01234500340.18", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01234500340.18"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Novartis Oncology Global Medical Affairs, One Health Plaza, East Hanover, NJ 07936, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kim", 
        "givenName": "D", 
        "id": "sg:person.01363026357.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01363026357.23"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Novartis Oncology Global Development, CH-4002 Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Anak", 
        "givenName": "O", 
        "id": "sg:person.0760541065.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0760541065.16"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Novartis Oncology Biometrics and Data Management, 180 Park Avenue, Florham Park, NJ 07936, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Panneerselvam", 
        "givenName": "A", 
        "id": "sg:person.0637422257.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0637422257.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institut Gustave Roussy", 
          "id": "https://www.grid.ac/institutes/grid.14925.3b", 
          "name": [
            "Institut Gustave Roussy, 114 rue Edouard Vaillant, 94805 Villejuif, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Escudier", 
        "givenName": "B", 
        "id": "sg:person.01304252172.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01304252172.82"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1634/theoncologist.2011-s2-32", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000139815"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1471-2407-11-105", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002984908", 
          "https://doi.org/10.1186/1471-2407-11-105"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdq206", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003680961"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdq206", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003680961"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa065044", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007947936"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.eururo.2010.06.032", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010947533"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1464-410x.2009.08972.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011839805"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1464-410x.2009.08972.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011839805"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.25219", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017587632"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.25219", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017587632"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.eururo.2010.09.008", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019549688"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.25327", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020612015"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ctrv.2011.12.009", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021127496"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2007.15.5416", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024770463"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa060655", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025111240"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/92.3.205", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032301848"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejca.2011.02.014", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038027579"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-009-1170-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042343030", 
          "https://doi.org/10.1007/s00280-009-1170-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-009-1170-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042343030", 
          "https://doi.org/10.1007/s00280-009-1170-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-009-1170-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042343030", 
          "https://doi.org/10.1007/s00280-009-1170-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(08)61039-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045744105"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejca.2008.12.010", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047395746"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2009.22.6480", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049703508"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1164/rccm.200911-1720oc", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051231076"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(11)61613-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052713041"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2009.23.9764", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052849919"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2010.28.15_suppl.e15132", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083945788"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2012-04", 
    "datePublishedReg": "2012-04-01", 
    "description": "BACKGROUND: A relevant percentage of patients with metastatic renal cell carcinoma develop intolerance to vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFr-TKIs) and require careful selection of subsequent treatment. This retrospective analysis evaluated the safety and efficacy of everolimus in patients enrolled in the phase-III RECORD-1 trial who discontinued previous VEGFr-TKI therapy because of toxicity.\nMETHODS: Patients with an adverse event (AE) as their primary reason for discontinuation of previous VEGFr-TKI therapy were included. Median progression-free survival (PFS) for VEGFr-TKI-intolerant patients in each arm was estimated using the Kaplan-Meier method, and effect on PFS (hazard ratio (HR)) was calculated using the Cox proportional hazard model.\nRESULTS: In VEGFr-TKI-intolerant patients (n=58, 14%), median PFS was 5.4 months with everolimus and 1.9 months with placebo (HR: 0.32; P=0.004). In sunitinib-intolerant patients (n=26), median PFS was 5.1 months with everolimus and 2.8 months with placebo (HR: 0.28; P=0.033). Grade 3/4 AEs reported with everolimus in VEGFr-TKI-intolerant patients included infections (16%), fatigue (7%) and stomatitis (4%). The toxicity profile of everolimus was similar in the VEGFr-TKI-intolerant and overall study populations.\nCONCLUSION: Everolimus is well tolerated and efficacious with no increased toxicity in patients intolerant to VEGFr-TKI therapy.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1038/bjc.2012.89", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1017082", 
        "issn": [
          "0007-0920", 
          "1532-1827"
        ], 
        "name": "British Journal of Cancer", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "9", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "106"
      }
    ], 
    "name": "Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis", 
    "pagination": "1475", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "c7730bc4e612c1d07dc02ef546c5e92e8d1d325bfbe9e8ebb09df787c9a858ab"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "22441644"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "0370635"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/bjc.2012.89"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1041870192"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/bjc.2012.89", 
      "https://app.dimensions.ai/details/publication/pub.1041870192"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T21:26", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8687_00000436.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://www.nature.com/articles/bjc201289"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/bjc.2012.89'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/bjc.2012.89'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/bjc.2012.89'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/bjc.2012.89'


 

This table displays all metadata directly associated to this object as RDF triples.

327 TRIPLES      21 PREDICATES      72 URIs      42 LITERALS      30 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/bjc.2012.89 schema:about N012a67cb201d4c6fa924ada486869e28
2 N058b06b3d39545ffb655c358e41bd572
3 N1216226953ab46c98151ed9d3a1941a2
4 N1624e9756f8443919832df76e6f23702
5 N1f6cfccad46f4bccba47493717449e11
6 N31d0a81b282c413b98d113bb89175b91
7 N41167e0582e9471482612931ef196dc5
8 N5340d9526feb4d7496a9ba7c6488956e
9 N56ed7b6e6f034d93844c130d0a7a4de4
10 N5cfdac619a334f8596c93d009d04b56d
11 N71a6f4cb6b3d40b2af7aa4f0a9f57fa2
12 N753617cd03be4513b073d5751520cd04
13 N7f3fe252cc8e4ca9b99636e7ea5a16e7
14 N8984b33d40b0483da7865a1dace3e845
15 Na3eb5758b8a5449d89b84ea3d4ebdec8
16 Naaf70574257f45939b91ca26a9b3e952
17 Nb208d441af9c40c8b1c55f6a2edb3442
18 Nbe1f658b3832491fb916d19a4f0c0bf8
19 Nf7831b7434804ed0a5361095e997066d
20 Nfe0bfa4c3e0b4027a60854435d304e08
21 Nffb2c4afdc884481a555f186a1af1df5
22 anzsrc-for:11
23 anzsrc-for:1103
24 schema:author N6cb3bfc2169b40b48fbe35e226e5d989
25 schema:citation sg:pub.10.1007/s00280-009-1170-y
26 sg:pub.10.1186/1471-2407-11-105
27 https://doi.org/10.1002/cncr.25219
28 https://doi.org/10.1002/cncr.25327
29 https://doi.org/10.1016/j.ctrv.2011.12.009
30 https://doi.org/10.1016/j.ejca.2008.12.010
31 https://doi.org/10.1016/j.ejca.2011.02.014
32 https://doi.org/10.1016/j.eururo.2010.06.032
33 https://doi.org/10.1016/j.eururo.2010.09.008
34 https://doi.org/10.1016/s0140-6736(08)61039-9
35 https://doi.org/10.1016/s0140-6736(11)61613-9
36 https://doi.org/10.1056/nejmoa060655
37 https://doi.org/10.1056/nejmoa065044
38 https://doi.org/10.1093/annonc/mdq206
39 https://doi.org/10.1093/jnci/92.3.205
40 https://doi.org/10.1111/j.1464-410x.2009.08972.x
41 https://doi.org/10.1164/rccm.200911-1720oc
42 https://doi.org/10.1200/jco.2007.15.5416
43 https://doi.org/10.1200/jco.2009.22.6480
44 https://doi.org/10.1200/jco.2009.23.9764
45 https://doi.org/10.1200/jco.2010.28.15_suppl.e15132
46 https://doi.org/10.1634/theoncologist.2011-s2-32
47 schema:datePublished 2012-04
48 schema:datePublishedReg 2012-04-01
49 schema:description BACKGROUND: A relevant percentage of patients with metastatic renal cell carcinoma develop intolerance to vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFr-TKIs) and require careful selection of subsequent treatment. This retrospective analysis evaluated the safety and efficacy of everolimus in patients enrolled in the phase-III RECORD-1 trial who discontinued previous VEGFr-TKI therapy because of toxicity. METHODS: Patients with an adverse event (AE) as their primary reason for discontinuation of previous VEGFr-TKI therapy were included. Median progression-free survival (PFS) for VEGFr-TKI-intolerant patients in each arm was estimated using the Kaplan-Meier method, and effect on PFS (hazard ratio (HR)) was calculated using the Cox proportional hazard model. RESULTS: In VEGFr-TKI-intolerant patients (n=58, 14%), median PFS was 5.4 months with everolimus and 1.9 months with placebo (HR: 0.32; P=0.004). In sunitinib-intolerant patients (n=26), median PFS was 5.1 months with everolimus and 2.8 months with placebo (HR: 0.28; P=0.033). Grade 3/4 AEs reported with everolimus in VEGFr-TKI-intolerant patients included infections (16%), fatigue (7%) and stomatitis (4%). The toxicity profile of everolimus was similar in the VEGFr-TKI-intolerant and overall study populations. CONCLUSION: Everolimus is well tolerated and efficacious with no increased toxicity in patients intolerant to VEGFr-TKI therapy.
50 schema:genre research_article
51 schema:inLanguage en
52 schema:isAccessibleForFree true
53 schema:isPartOf N5dec5bb39d354791ab23e24635b7c40e
54 Ne07f2511b01646349e86c76e4351b47c
55 sg:journal.1017082
56 schema:name Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis
57 schema:pagination 1475
58 schema:productId N3d7429bbc9334adfb9bb93cfbbd5cacd
59 N427cfee471a64671a756eda062a36a09
60 N84072d86453b4de2bcafb55c3d469bc3
61 N98ad9540357147c999edfdd76bde4cb4
62 Nb354d11d4bff4acd892ea840712310d9
63 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041870192
64 https://doi.org/10.1038/bjc.2012.89
65 schema:sdDatePublished 2019-04-10T21:26
66 schema:sdLicense https://scigraph.springernature.com/explorer/license/
67 schema:sdPublisher Nfcc6f8b4d28342319a4924e41e004f37
68 schema:url https://www.nature.com/articles/bjc201289
69 sgo:license sg:explorer/license/
70 sgo:sdDataset articles
71 rdf:type schema:ScholarlyArticle
72 N012a67cb201d4c6fa924ada486869e28 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
73 schema:name Aged, 80 and over
74 rdf:type schema:DefinedTerm
75 N028cda9734284be8b83e38f1ece622ba rdf:first sg:person.01234500340.18
76 rdf:rest N5708a35e4315499ea6a6ff389e87b4bc
77 N04ae2f3234404c8d8b903fb13e4b23ce rdf:first sg:person.0626761272.86
78 rdf:rest Nf95a0d100a844b219e83e888ab3d90d6
79 N058b06b3d39545ffb655c358e41bd572 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
80 schema:name Everolimus
81 rdf:type schema:DefinedTerm
82 N1216226953ab46c98151ed9d3a1941a2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
83 schema:name Double-Blind Method
84 rdf:type schema:DefinedTerm
85 N1624e9756f8443919832df76e6f23702 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
86 schema:name Male
87 rdf:type schema:DefinedTerm
88 N1f6cfccad46f4bccba47493717449e11 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
89 schema:name Kidney Neoplasms
90 rdf:type schema:DefinedTerm
91 N31d0a81b282c413b98d113bb89175b91 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
92 schema:name Retrospective Studies
93 rdf:type schema:DefinedTerm
94 N36463dc74a444a00b442963456cdbff1 schema:name Novartis Oncology Global Development, CH-4002 Basel, Switzerland
95 rdf:type schema:Organization
96 N3d7429bbc9334adfb9bb93cfbbd5cacd schema:name doi
97 schema:value 10.1038/bjc.2012.89
98 rdf:type schema:PropertyValue
99 N41167e0582e9471482612931ef196dc5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
100 schema:name Adult
101 rdf:type schema:DefinedTerm
102 N427cfee471a64671a756eda062a36a09 schema:name nlm_unique_id
103 schema:value 0370635
104 rdf:type schema:PropertyValue
105 N5340d9526feb4d7496a9ba7c6488956e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
106 schema:name Aged
107 rdf:type schema:DefinedTerm
108 N56ed7b6e6f034d93844c130d0a7a4de4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Immunosuppressive Agents
110 rdf:type schema:DefinedTerm
111 N5708a35e4315499ea6a6ff389e87b4bc rdf:first sg:person.01363026357.23
112 rdf:rest Nd6768123b9c348daa765257969af9227
113 N5cfdac619a334f8596c93d009d04b56d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Carcinoma, Renal Cell
115 rdf:type schema:DefinedTerm
116 N5dec5bb39d354791ab23e24635b7c40e schema:volumeNumber 106
117 rdf:type schema:PublicationVolume
118 N6cb3bfc2169b40b48fbe35e226e5d989 rdf:first sg:person.0672107754.22
119 rdf:rest N04ae2f3234404c8d8b903fb13e4b23ce
120 N71a6f4cb6b3d40b2af7aa4f0a9f57fa2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name International Agencies
122 rdf:type schema:DefinedTerm
123 N753617cd03be4513b073d5751520cd04 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Receptors, Vascular Endothelial Growth Factor
125 rdf:type schema:DefinedTerm
126 N7f3fe252cc8e4ca9b99636e7ea5a16e7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Middle Aged
128 rdf:type schema:DefinedTerm
129 N84072d86453b4de2bcafb55c3d469bc3 schema:name dimensions_id
130 schema:value pub.1041870192
131 rdf:type schema:PropertyValue
132 N8984b33d40b0483da7865a1dace3e845 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Survival Rate
134 rdf:type schema:DefinedTerm
135 N98ad9540357147c999edfdd76bde4cb4 schema:name readcube_id
136 schema:value c7730bc4e612c1d07dc02ef546c5e92e8d1d325bfbe9e8ebb09df787c9a858ab
137 rdf:type schema:PropertyValue
138 Na3eb5758b8a5449d89b84ea3d4ebdec8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Protein Kinase Inhibitors
140 rdf:type schema:DefinedTerm
141 Naaf70574257f45939b91ca26a9b3e952 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Salvage Therapy
143 rdf:type schema:DefinedTerm
144 Nae33f664ea554ae18ad3c22bb7d3dd77 rdf:first sg:person.0664152550.77
145 rdf:rest Ne3a427266dd94d28985dd64a664a2579
146 Nb208d441af9c40c8b1c55f6a2edb3442 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Humans
148 rdf:type schema:DefinedTerm
149 Nb354d11d4bff4acd892ea840712310d9 schema:name pubmed_id
150 schema:value 22441644
151 rdf:type schema:PropertyValue
152 Nbe1f658b3832491fb916d19a4f0c0bf8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Sirolimus
154 rdf:type schema:DefinedTerm
155 Nc58122dda8104262b2c81843eb4b4f83 rdf:first sg:person.0637422257.36
156 rdf:rest Ne085c798e2254d6a9c9d8249ece39df6
157 Nd6768123b9c348daa765257969af9227 rdf:first sg:person.0760541065.16
158 rdf:rest Nc58122dda8104262b2c81843eb4b4f83
159 Nd93a46aea24042b89a9bf3aaed7e10cc schema:name Novartis Oncology Global Medical Affairs, One Health Plaza, East Hanover, NJ 07936, USA
160 rdf:type schema:Organization
161 Ne07f2511b01646349e86c76e4351b47c schema:issueNumber 9
162 rdf:type schema:PublicationIssue
163 Ne085c798e2254d6a9c9d8249ece39df6 rdf:first sg:person.01304252172.82
164 rdf:rest rdf:nil
165 Ne1bcd3f5b1264501a93d1c816aa7c0ed rdf:first sg:person.01077045011.19
166 rdf:rest N028cda9734284be8b83e38f1ece622ba
167 Ne3a427266dd94d28985dd64a664a2579 rdf:first sg:person.01213300245.49
168 rdf:rest Nf2e5d7091f404ad4a9bb587fd0b55f36
169 Nf2e5d7091f404ad4a9bb587fd0b55f36 rdf:first sg:person.01315730111.15
170 rdf:rest Ne1bcd3f5b1264501a93d1c816aa7c0ed
171 Nf7831b7434804ed0a5361095e997066d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
172 schema:name Lymphatic Metastasis
173 rdf:type schema:DefinedTerm
174 Nf95a0d100a844b219e83e888ab3d90d6 rdf:first sg:person.01100733105.43
175 rdf:rest Nae33f664ea554ae18ad3c22bb7d3dd77
176 Nf9a2e61c420647a289f882e7c0b29a9d schema:name Novartis Oncology Biometrics and Data Management, 180 Park Avenue, Florham Park, NJ 07936, USA
177 rdf:type schema:Organization
178 Nfa384530492c4ac0a93a18174d2e9a9c schema:name US Oncology/Baylor–Sammons Cancer Center, 3535 Worth Street, Dallas, TX 75246, USA
179 rdf:type schema:Organization
180 Nfcc6f8b4d28342319a4924e41e004f37 schema:name Springer Nature - SN SciGraph project
181 rdf:type schema:Organization
182 Nfe0bfa4c3e0b4027a60854435d304e08 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
183 schema:name Treatment Outcome
184 rdf:type schema:DefinedTerm
185 Nffb2c4afdc884481a555f186a1af1df5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
186 schema:name Female
187 rdf:type schema:DefinedTerm
188 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
189 schema:name Medical and Health Sciences
190 rdf:type schema:DefinedTerm
191 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
192 schema:name Clinical Sciences
193 rdf:type schema:DefinedTerm
194 sg:journal.1017082 schema:issn 0007-0920
195 1532-1827
196 schema:name British Journal of Cancer
197 rdf:type schema:Periodical
198 sg:person.01077045011.19 schema:affiliation https://www.grid.ac/institutes/grid.414339.8
199 schema:familyName Ravaud
200 schema:givenName A
201 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01077045011.19
202 rdf:type schema:Person
203 sg:person.01100733105.43 schema:affiliation https://www.grid.ac/institutes/grid.419425.f
204 schema:familyName Porta
205 schema:givenName C
206 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01100733105.43
207 rdf:type schema:Person
208 sg:person.01213300245.49 schema:affiliation https://www.grid.ac/institutes/grid.428486.4
209 schema:familyName Calvo
210 schema:givenName E
211 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01213300245.49
212 rdf:type schema:Person
213 sg:person.01234500340.18 schema:affiliation https://www.grid.ac/institutes/grid.51462.34
214 schema:familyName Motzer
215 schema:givenName R
216 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01234500340.18
217 rdf:type schema:Person
218 sg:person.01304252172.82 schema:affiliation https://www.grid.ac/institutes/grid.14925.3b
219 schema:familyName Escudier
220 schema:givenName B
221 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01304252172.82
222 rdf:type schema:Person
223 sg:person.01315730111.15 schema:affiliation https://www.grid.ac/institutes/grid.10423.34
224 schema:familyName Grünwald
225 schema:givenName V
226 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01315730111.15
227 rdf:type schema:Person
228 sg:person.01363026357.23 schema:affiliation Nd93a46aea24042b89a9bf3aaed7e10cc
229 schema:familyName Kim
230 schema:givenName D
231 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01363026357.23
232 rdf:type schema:Person
233 sg:person.0626761272.86 schema:affiliation Nfa384530492c4ac0a93a18174d2e9a9c
234 schema:familyName Hutson
235 schema:givenName T E
236 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0626761272.86
237 rdf:type schema:Person
238 sg:person.0637422257.36 schema:affiliation Nf9a2e61c420647a289f882e7c0b29a9d
239 schema:familyName Panneerselvam
240 schema:givenName A
241 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0637422257.36
242 rdf:type schema:Person
243 sg:person.0664152550.77 schema:affiliation https://www.grid.ac/institutes/grid.50956.3f
244 schema:familyName Figlin
245 schema:givenName R A
246 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0664152550.77
247 rdf:type schema:Person
248 sg:person.0672107754.22 schema:affiliation https://www.grid.ac/institutes/grid.416351.4
249 schema:familyName Bracarda
250 schema:givenName S
251 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0672107754.22
252 rdf:type schema:Person
253 sg:person.0760541065.16 schema:affiliation N36463dc74a444a00b442963456cdbff1
254 schema:familyName Anak
255 schema:givenName O
256 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0760541065.16
257 rdf:type schema:Person
258 sg:pub.10.1007/s00280-009-1170-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1042343030
259 https://doi.org/10.1007/s00280-009-1170-y
260 rdf:type schema:CreativeWork
261 sg:pub.10.1186/1471-2407-11-105 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002984908
262 https://doi.org/10.1186/1471-2407-11-105
263 rdf:type schema:CreativeWork
264 https://doi.org/10.1002/cncr.25219 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017587632
265 rdf:type schema:CreativeWork
266 https://doi.org/10.1002/cncr.25327 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020612015
267 rdf:type schema:CreativeWork
268 https://doi.org/10.1016/j.ctrv.2011.12.009 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021127496
269 rdf:type schema:CreativeWork
270 https://doi.org/10.1016/j.ejca.2008.12.010 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047395746
271 rdf:type schema:CreativeWork
272 https://doi.org/10.1016/j.ejca.2011.02.014 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038027579
273 rdf:type schema:CreativeWork
274 https://doi.org/10.1016/j.eururo.2010.06.032 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010947533
275 rdf:type schema:CreativeWork
276 https://doi.org/10.1016/j.eururo.2010.09.008 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019549688
277 rdf:type schema:CreativeWork
278 https://doi.org/10.1016/s0140-6736(08)61039-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045744105
279 rdf:type schema:CreativeWork
280 https://doi.org/10.1016/s0140-6736(11)61613-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052713041
281 rdf:type schema:CreativeWork
282 https://doi.org/10.1056/nejmoa060655 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025111240
283 rdf:type schema:CreativeWork
284 https://doi.org/10.1056/nejmoa065044 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007947936
285 rdf:type schema:CreativeWork
286 https://doi.org/10.1093/annonc/mdq206 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003680961
287 rdf:type schema:CreativeWork
288 https://doi.org/10.1093/jnci/92.3.205 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032301848
289 rdf:type schema:CreativeWork
290 https://doi.org/10.1111/j.1464-410x.2009.08972.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1011839805
291 rdf:type schema:CreativeWork
292 https://doi.org/10.1164/rccm.200911-1720oc schema:sameAs https://app.dimensions.ai/details/publication/pub.1051231076
293 rdf:type schema:CreativeWork
294 https://doi.org/10.1200/jco.2007.15.5416 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024770463
295 rdf:type schema:CreativeWork
296 https://doi.org/10.1200/jco.2009.22.6480 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049703508
297 rdf:type schema:CreativeWork
298 https://doi.org/10.1200/jco.2009.23.9764 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052849919
299 rdf:type schema:CreativeWork
300 https://doi.org/10.1200/jco.2010.28.15_suppl.e15132 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083945788
301 rdf:type schema:CreativeWork
302 https://doi.org/10.1634/theoncologist.2011-s2-32 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000139815
303 rdf:type schema:CreativeWork
304 https://www.grid.ac/institutes/grid.10423.34 schema:alternateName Hannover Medical School
305 schema:name Medical School Hannover, Carl Neuberg Street 1, D-30627 Hannover, Germany
306 rdf:type schema:Organization
307 https://www.grid.ac/institutes/grid.14925.3b schema:alternateName Institut Gustave Roussy
308 schema:name Institut Gustave Roussy, 114 rue Edouard Vaillant, 94805 Villejuif, France
309 rdf:type schema:Organization
310 https://www.grid.ac/institutes/grid.414339.8 schema:alternateName Hôpital Saint-André
311 schema:name Hôpital Saint André CHU, 1 rue Jean Burguet, 33075 Bordeaux, France
312 rdf:type schema:Organization
313 https://www.grid.ac/institutes/grid.416351.4 schema:alternateName Ospedale San Donato
314 schema:name Ospedale San Donato USL8, Istituto Toscano Tumori (ITT), Via Pietro Nenni, 20 52100 Arezzo, Italy
315 rdf:type schema:Organization
316 https://www.grid.ac/institutes/grid.419425.f schema:alternateName Policlinico San Matteo Fondazione
317 schema:name IRCCS San Matteo University Hospital Foundation, Piazzale C. Golgi 19, Pavia I-27100, Italy
318 rdf:type schema:Organization
319 https://www.grid.ac/institutes/grid.428486.4 schema:alternateName HM Hospitales
320 schema:name START Madrid, Centro Integral Oncológico Clara Campal, Hospital Madrid Norte Sanchinarro, 28050 Madrid, Spain
321 rdf:type schema:Organization
322 https://www.grid.ac/institutes/grid.50956.3f schema:alternateName Cedars-Sinai Medical Center
323 schema:name Samuel Oschin Comprehensive Cancer Institute, Cedars–Sinai Medical Center, 8700 Beverly Boulevard, AC 1085 North Tower, Los Angeles, CA 90048, USA
324 rdf:type schema:Organization
325 https://www.grid.ac/institutes/grid.51462.34 schema:alternateName Memorial Sloan Kettering Cancer Center
326 schema:name Memorial Sloan–Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
327 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...